VY-AADC01 gene therapy in Parkinson's disease: Interim results of the on-going Phase 1b PD-1101 trial

被引：0
|
作者：
Larson, P.
Bankiewicz, K.
Van Laar, A.
Richardson, R.
Ravina, B.
Kells, A.
Boot, B.
Martin, A.
Thompson, M.
Christine, C.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
315
引用
收藏
页码：S137 / S138
页数：2
相关论文
共 43 条
  • [21] A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator
    den Heijer, Jonas M.
    Kruithof, Annelieke C.
    Moerland, Matthijs
    Walker, Mike
    Dudgeon, Lindsay
    Justman, Craig
    Solomini, Imelda
    Splitalny, Leslie
    Leymarie, Nancy
    Khatri, Kshitij
    Cullen, Valerie C.
    Hilt, Dana C.
    Groeneveld, Geert Jan
    Lansbury, Peter
    MOVEMENT DISORDERS, 2023, 38 (07) : 1197 - 1208
  • [22] Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
    Per Svenningsson
    Anders Johansson
    Dag Nyholm
    Panagiota Tsitsi
    Fredrik Hansson
    Clas Sonesson
    Joakim Tedroff
    npj Parkinson's Disease, 4
  • [23] Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial
    Svenningsson, Per
    Johansson, Anders
    Nyholm, Dag
    Tsitsi, Panagiota
    Hansson, Fredrik
    Sonesson, Clas
    Tedroff, Joakim
    NPJ PARKINSONS DISEASE, 2018, 4
  • [24] QR-421a RNA therapy in retinitis pigmentosa due to mutations in USH2A: Stellar trial Phase[AP1] 1b/2 interim results
    Audo, Isabelle
    Birch, David G.
    Jayasundera, K. Thiran
    Meunier, Isabelle
    Huckfeldt, Rachel M.
    Koenekoop, Robert K.
    Yang, Paul
    de Cock, Edouard P. M.
    Dahler, Ellen C.
    Taylor, John
    Shams, Naveed
    Girach, Aniz
    ACTA OPHTHALMOLOGICA, 2022, 100
  • [25] Results from a Phase 1b Study of UCB0599, an Orally Available, Brain-penetrant Inhibitor of Alphasynuclein (ASYN) Misfolding in People Living with Parkinson's Disease (PD)
    Genius, Just
    Dastros-Pitei, Daniela
    Detalle, Laurent
    Domange, Coralie
    Kadima, Helene
    Key-Prato, Maria
    Long, Jeff
    Mathy, Francois-Xavier
    Schmidt, Astrid
    Smit, Johan W.
    Streffer, Johannes
    Basile, Peter
    NEUROLOGY, 2021, 96 (15)
  • [26] Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease: Results from an Open-Label, Phase I Trial
    Muramatsu, Shin-Ichi
    Fujimoto, Ken-Ichi
    Kato, Seiya
    Asari, Sayaka
    Mizukami, Hiroaki
    Ikeguchi, Kunihiko
    Kawakami, Tadataka
    Urabe, Masashi
    Kume, Akihiro
    Sato, Toshihiko
    Watanabe, Eiju
    Ozawa, Keiya
    Nakano, Imaharu
    MOLECULAR THERAPY, 2009, 17 : S168 - S168
  • [27] Treatment monitoring using objective and frequent digital testing in the D1PAM (LY3154207) phase 1B Parkinson's disease clinical trial
    Wang, J.
    Battioui, C.
    Li, Y.
    Calvin, A.
    Wu, L.
    Romano, A.
    Miller, B.
    MOVEMENT DISORDERS, 2019, 34 : S95 - S95
  • [28] Use digital sensor and deep learning to evaluate motor performance in the D1PAM (LY3154207) phase 1B Parkinson's disease clinical trial
    Li, Y.
    Guan, Y.
    Wang, J.
    Calvin, A.
    Kyle, J.
    Miller, B.
    MOVEMENT DISORDERS, 2019, 34 : S58 - S58
  • [29] Results of an Open Label, Dose Escalating, Phase 1 Clinical Trial Evaluating the Safety of a Human Neural Stem Cell Based Therapy in Parkinson's Disease
    Kern, Russell
    Garitaonandia, Ibon
    Gonzalez, Rodolfo
    Sherman, Glenn
    Semechkin, Andrey
    Braine, Emma
    Nair, Girish
    Evans, Andrew
    NEUROLOGY, 2019, 92 (15)
  • [30] Design of Phase 1/2a Study of AAV9-Based Gene Therapy for Parkinson's Disease with Pathogenic GBA1 Mutations (PROPEL Trial)
    Uspenskaya, Olga
    Mahoney, Erin
    Verselis, Lynne
    Lowrey, Mark
    Velaga, Jenny
    Sevigny, Jeffrey
    NEUROLOGY, 2020, 94 (15)
12345